Investing.com -- U.S. markets fell on Friday, in a mixed week, but there were plenty of big-name moves. Here are Investing.com’s stocks of the week.
Nvidia (NASDAQ:NVDA)
There is only one place to start. Nvidia reported its latest quarterly earnings on Wednesday, topping consensus earnings and revenue expectations. However, the chipmaker flagged an $8 billion hit to Q2 guidance from the U.S. ban on chip sales to China.
Nvidia shares are up around 2.4% in the last week.
“The report was favorable in that all of the investor concerns heading into the quarter have by now been addressed - rack production, China (now out of numbers) and AI diffusion (not being enforced),” analysts at Wolfe Research said in a note reacting to the earnings release.
“With the concerns now addressed, the stock up and a bullish outlook for 2H, we think the pain trade for NVDA is higher.”
Regeneron (NASDAQ:REGN)
Regeneron shares plummeted Friday after the company, alongside Sanofi (NASDAQ:SNY), reported mixed results from two phase 3 trials of their investigational chronic obstructive pulmonary disease (COPD) treatment, Itepekimab.
At the time of writing, the stock is down around 19%. For the week, REGN shares have declined about 16.7%.
"We think Itepekimab’s disappointing data creates a big challenge for REGN in the long term," Wells Fargo analysts said in a note reacting to the news. "We also see consensus down revision potential for Eylea. We are downgrading to Equal Weight due to a lack of near-term value-unlocking events. New PT $580/sh."
Unity
Unity shares saw strong gains this week, rising by more than 20%. The rise started on Wednesday with a more than 12% increase.
The stock saw notable call option activity all week. While it pulled back slightly on Thursday, an upgrade from Jefferies helped push it higher on Friday.
“We are upgrading U based on the view the improved Vector ad model can drive accelerating rev growth in FY26 and beyond,” Jefferies wrote in its note to clients. “With high incremental EBITDA margins in the Grow business, we believe the risk-reward is favorable as [we] see potential for significant EBITDA upside.”
Veeva Systems (NYSE:VEEV)
Alongside Nvidia, VEEV was another earnings winner, with the company topping earnings and revenue expectations when it reported on Wednesday. The firm also provided Q2 and full-year guidance well above analyst expectations.
The stock is up more than 18% in the last week.
“Veeva deserves credit for navigating through a tumultuous backdrop in Life Sciences that has tripped up most companies selling into this vertical,” Morgan Stanley said in a note following the results.
E.L.F Beauty
E.L.F. Beauty’s stock is up more than 34% in the last week. The positive performance, primarily driven by an over 23% surge on Thursday, comes after the company announced a $1 billion deal to acquire rhode, a lifestyle beauty brand founded by Hailey Bieber.
In reaction to the news, Jefferies analysts stated: “We are excited by the deal as we view it as additive to the ELF portfolio with significant runway ahead.”
The company also reported its quarterly results after the close on Wednesday, topping consensus expectations.
"March-Q sales, EBITDA, and EPS came in ahead of Street. Sales driven by volume, with some offset from mix,” added Jefferies.
Tempus AI
Finally, Tempus AI plunged by 19.2% in Wednesday’s session after a short report on the stock was released by Spruce Point. It is down 12.6% in the last week.
Spruce Point Management stated: "After conducting a forensic financial review of Tempus AI, Inc. (Nasdaq: TEM) a healthcare technology company that provides AI-enabled precision medicine solutions, Spruce Point believes that the Company is run by leaders who have a dubious history, is participating in aggressive and suspicious accounting practices, and relies on weakening partnerships.”
Furthermore, the short seller said it believes owning shares of Tempus is a “poor risk/reward based on a flawed equity growth story, owing its appeal to the AI hype despite only 2% of revenue stemming from AI applications.”
The firm sees a potential 50%-60% long-term downside and market underperformance risk for the stock.
